Loading…
Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers
Cancer Associated Fibroblasts (CAFs) are thought to regulate tumor growth and metastasis. Fibroblast Activating Protein 1 (FAP-1) is a marker for fibroblast activation and by many recognized as the main marker of CAFs. Alpha Smooth Muscle Actin (α-SMA) is a general myofibroblast marker, and can be u...
Saved in:
Published in: | PloS one 2015-08, Vol.10 (8), p.e0134965-e0134965 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c715t-dc983d6df2607f7890ff8a65e8c3323c9f0ab9d04401cc776d9e5819feef4eee3 |
---|---|
cites | cdi_FETCH-LOGICAL-c715t-dc983d6df2607f7890ff8a65e8c3323c9f0ab9d04401cc776d9e5819feef4eee3 |
container_end_page | e0134965 |
container_issue | 8 |
container_start_page | e0134965 |
container_title | PloS one |
container_volume | 10 |
creator | Kilvaer, Thomas K Khanehkenari, Mehrdad Rakaee Hellevik, Turid Al-Saad, Samer Paulsen, Erna-Elise Bremnes, Roy M Busund, Lill-Tove Donnem, Tom Martinez, Inigo Z |
description | Cancer Associated Fibroblasts (CAFs) are thought to regulate tumor growth and metastasis. Fibroblast Activating Protein 1 (FAP-1) is a marker for fibroblast activation and by many recognized as the main marker of CAFs. Alpha Smooth Muscle Actin (α-SMA) is a general myofibroblast marker, and can be used to identify CAFs. This study investigates the prognostic impact of FAP-1 and α-SMA in non-small cell lung cancer (NSCLC) patients and correlates their expression to 105 proteins investigated in the same cohort.
Tumor specimens from 536 NSCLC patients were obtained and tissue micro-arrays were constructed. Immunohistochemistry was used to evaluate the expression of FAP-1 and α-SMA and explore their impact on survival and association with other tumor molecular markers in NSCLC patients.
High expression of FAP-1, but not α-SMA, in squamous cell carcinoma (SCC, P = 0.043, HR = 0.63 95% CI 0.40-0.99) was significantly associated with increased disease-specific survival. FAP-1 and α-SMA were not significantly correlated to each other. Analyses of FAP-1 and α-SMA associated with other tumor-related proteins revealed histotype-specific correlation patterns.
The presence of FAP-1 expressing CAFs is an indicator of positive outcome for NSCLC-SCC patients. In addition, correlation analyses suggest FAP-1 and α-SMA to label different subsets of fibroblasts and their associations with other tumor-related proteins diverge according to histological subtype. |
doi_str_mv | 10.1371/journal.pone.0134965 |
format | article |
fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1702213103</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A432850705</galeid><doaj_id>oai_doaj_org_article_35c031e2621049f9999f832e29f6aaac</doaj_id><sourcerecordid>A432850705</sourcerecordid><originalsourceid>FETCH-LOGICAL-c715t-dc983d6df2607f7890ff8a65e8c3323c9f0ab9d04401cc776d9e5819feef4eee3</originalsourceid><addsrcrecordid>eNqNk9tuEzEQhlcIREvhDRBYQkJwkeDDntwLpCiisFKgiBZuLcc7TlwcO9heTk-Pm6SlQb1g92It7ze_Pf_MFMVjgseENeTVhR-Ck3a89g7GmLCS19Wd4pBwRkc1xezujfVB8SDGC4wr1tb1_eKA1rSirOGHxe-pdAoCmsTolZEJenRi5sHPrYwpIuPQWZILQN2o67oJ-nA2nU2P0cfgF87HZBTqVmupEpKuR-dLMAFNfQhgZTLeRfTDpCU6H1Y-oPfeghqszCsZvkKID4t7WtoIj3bfo-LzyZvz6bvR7PRtN53MRqohVRr1iresr3tNa9zopuVY61bWFbSKMcoU11jOeY_LEhOlmqbuOVQt4RpAlwDAjoqnW9219VHsbIuCNJhSwghmmei2RO_lhVgHs5Lhl_DSiM2GDwshQ07WgmCVwoxANpDgkmueH90yCpTrWkqpstbr3WnDfAW9ApeCtHui-3-cWYqF_y7KinLKeBZ4shVQwWSHnXA-SEEwZo1oa04y8GJ3QvDfBohJrExUYK104IdNYoyWrK3KjD77B709_R21kDlD47TPF1OXomJSMtpWuMmdc1SMb6Hy28PKqNyE2uT9vYCXewGZSfAzLeQQo-jOPv0_e_pln31-g12CtGkZvR02HbcPlldO-hgD6OsqECwuZ-jKDXE5Q2I3Q38LsK3TddDV0LA_J0UUgQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1702213103</pqid></control><display><type>article</type><title>Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers</title><source>PubMed (Medline)</source><source>NORA - Norwegian Open Research Archives</source><source>Publicly Available Content (ProQuest)</source><creator>Kilvaer, Thomas K ; Khanehkenari, Mehrdad Rakaee ; Hellevik, Turid ; Al-Saad, Samer ; Paulsen, Erna-Elise ; Bremnes, Roy M ; Busund, Lill-Tove ; Donnem, Tom ; Martinez, Inigo Z</creator><contributor>Gullberg, Donald</contributor><creatorcontrib>Kilvaer, Thomas K ; Khanehkenari, Mehrdad Rakaee ; Hellevik, Turid ; Al-Saad, Samer ; Paulsen, Erna-Elise ; Bremnes, Roy M ; Busund, Lill-Tove ; Donnem, Tom ; Martinez, Inigo Z ; Gullberg, Donald</creatorcontrib><description>Cancer Associated Fibroblasts (CAFs) are thought to regulate tumor growth and metastasis. Fibroblast Activating Protein 1 (FAP-1) is a marker for fibroblast activation and by many recognized as the main marker of CAFs. Alpha Smooth Muscle Actin (α-SMA) is a general myofibroblast marker, and can be used to identify CAFs. This study investigates the prognostic impact of FAP-1 and α-SMA in non-small cell lung cancer (NSCLC) patients and correlates their expression to 105 proteins investigated in the same cohort.
Tumor specimens from 536 NSCLC patients were obtained and tissue micro-arrays were constructed. Immunohistochemistry was used to evaluate the expression of FAP-1 and α-SMA and explore their impact on survival and association with other tumor molecular markers in NSCLC patients.
High expression of FAP-1, but not α-SMA, in squamous cell carcinoma (SCC, P = 0.043, HR = 0.63 95% CI 0.40-0.99) was significantly associated with increased disease-specific survival. FAP-1 and α-SMA were not significantly correlated to each other. Analyses of FAP-1 and α-SMA associated with other tumor-related proteins revealed histotype-specific correlation patterns.
The presence of FAP-1 expressing CAFs is an indicator of positive outcome for NSCLC-SCC patients. In addition, correlation analyses suggest FAP-1 and α-SMA to label different subsets of fibroblasts and their associations with other tumor-related proteins diverge according to histological subtype.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0134965</identifier><identifier>PMID: 26252379</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Actin ; Actins - metabolism ; Aged ; Antigens ; Biology ; Biomarkers, Tumor - metabolism ; Cancer ; Cancer patients ; Carcinoma, Non-Small-Cell Lung - metabolism ; Carcinoma, Non-Small-Cell Lung - pathology ; Care and treatment ; Chemotherapy ; Clinical medical disciplines: 750 ; Clinical medicine ; Cohort Studies ; Correlation ; Correlation analysis ; Development and progression ; Disease-Free Survival ; Female ; Fibroblasts ; Fibroblasts - metabolism ; Fibroblasts - pathology ; Health aspects ; Hospitals ; Humans ; Immunohistochemistry ; Immunotherapy ; Klinisk medisinske fag: 750 ; Lung cancer ; Lung diseases ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Male ; Markers ; Medical disciplines: 700 ; Medical prognosis ; Medicine ; Medisinske Fag: 700 ; Metastases ; Middle Aged ; Molecular chains ; Muscle proteins ; Muscles ; Neoplasm Staging ; Non-small cell lung cancer ; Non-small cell lung carcinoma ; Observer Variation ; Oncology ; Oncology: 762 ; Onkologi: 762 ; Pathology ; Patient outcomes ; Patients ; Physiological aspects ; Prognosis ; Protein Tyrosine Phosphatase, Non-Receptor Type 13 - metabolism ; Proteins ; Risk factors ; Smooth muscle ; Squamous cell carcinoma ; Statistics, Nonparametric ; Stromal Cells - metabolism ; Stromal Cells - pathology ; Studies ; Survival ; Tissue Array Analysis ; Tumors ; VDP ; Wound healing</subject><ispartof>PloS one, 2015-08, Vol.10 (8), p.e0134965-e0134965</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Kilvaer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>info:eu-repo/semantics/openAccess</rights><rights>2015 Kilvaer et al 2015 Kilvaer et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c715t-dc983d6df2607f7890ff8a65e8c3323c9f0ab9d04401cc776d9e5819feef4eee3</citedby><cites>FETCH-LOGICAL-c715t-dc983d6df2607f7890ff8a65e8c3323c9f0ab9d04401cc776d9e5819feef4eee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1702213103/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1702213103?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,26567,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26252379$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Gullberg, Donald</contributor><creatorcontrib>Kilvaer, Thomas K</creatorcontrib><creatorcontrib>Khanehkenari, Mehrdad Rakaee</creatorcontrib><creatorcontrib>Hellevik, Turid</creatorcontrib><creatorcontrib>Al-Saad, Samer</creatorcontrib><creatorcontrib>Paulsen, Erna-Elise</creatorcontrib><creatorcontrib>Bremnes, Roy M</creatorcontrib><creatorcontrib>Busund, Lill-Tove</creatorcontrib><creatorcontrib>Donnem, Tom</creatorcontrib><creatorcontrib>Martinez, Inigo Z</creatorcontrib><title>Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Cancer Associated Fibroblasts (CAFs) are thought to regulate tumor growth and metastasis. Fibroblast Activating Protein 1 (FAP-1) is a marker for fibroblast activation and by many recognized as the main marker of CAFs. Alpha Smooth Muscle Actin (α-SMA) is a general myofibroblast marker, and can be used to identify CAFs. This study investigates the prognostic impact of FAP-1 and α-SMA in non-small cell lung cancer (NSCLC) patients and correlates their expression to 105 proteins investigated in the same cohort.
Tumor specimens from 536 NSCLC patients were obtained and tissue micro-arrays were constructed. Immunohistochemistry was used to evaluate the expression of FAP-1 and α-SMA and explore their impact on survival and association with other tumor molecular markers in NSCLC patients.
High expression of FAP-1, but not α-SMA, in squamous cell carcinoma (SCC, P = 0.043, HR = 0.63 95% CI 0.40-0.99) was significantly associated with increased disease-specific survival. FAP-1 and α-SMA were not significantly correlated to each other. Analyses of FAP-1 and α-SMA associated with other tumor-related proteins revealed histotype-specific correlation patterns.
The presence of FAP-1 expressing CAFs is an indicator of positive outcome for NSCLC-SCC patients. In addition, correlation analyses suggest FAP-1 and α-SMA to label different subsets of fibroblasts and their associations with other tumor-related proteins diverge according to histological subtype.</description><subject>Actin</subject><subject>Actins - metabolism</subject><subject>Aged</subject><subject>Antigens</subject><subject>Biology</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Carcinoma, Non-Small-Cell Lung - metabolism</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical medical disciplines: 750</subject><subject>Clinical medicine</subject><subject>Cohort Studies</subject><subject>Correlation</subject><subject>Correlation analysis</subject><subject>Development and progression</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Fibroblasts</subject><subject>Fibroblasts - metabolism</subject><subject>Fibroblasts - pathology</subject><subject>Health aspects</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Immunotherapy</subject><subject>Klinisk medisinske fag: 750</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Markers</subject><subject>Medical disciplines: 700</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medisinske Fag: 700</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Molecular chains</subject><subject>Muscle proteins</subject><subject>Muscles</subject><subject>Neoplasm Staging</subject><subject>Non-small cell lung cancer</subject><subject>Non-small cell lung carcinoma</subject><subject>Observer Variation</subject><subject>Oncology</subject><subject>Oncology: 762</subject><subject>Onkologi: 762</subject><subject>Pathology</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Physiological aspects</subject><subject>Prognosis</subject><subject>Protein Tyrosine Phosphatase, Non-Receptor Type 13 - metabolism</subject><subject>Proteins</subject><subject>Risk factors</subject><subject>Smooth muscle</subject><subject>Squamous cell carcinoma</subject><subject>Statistics, Nonparametric</subject><subject>Stromal Cells - metabolism</subject><subject>Stromal Cells - pathology</subject><subject>Studies</subject><subject>Survival</subject><subject>Tissue Array Analysis</subject><subject>Tumors</subject><subject>VDP</subject><subject>Wound healing</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>3HK</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tuEzEQhlcIREvhDRBYQkJwkeDDntwLpCiisFKgiBZuLcc7TlwcO9heTk-Pm6SlQb1g92It7ze_Pf_MFMVjgseENeTVhR-Ck3a89g7GmLCS19Wd4pBwRkc1xezujfVB8SDGC4wr1tb1_eKA1rSirOGHxe-pdAoCmsTolZEJenRi5sHPrYwpIuPQWZILQN2o67oJ-nA2nU2P0cfgF87HZBTqVmupEpKuR-dLMAFNfQhgZTLeRfTDpCU6H1Y-oPfeghqszCsZvkKID4t7WtoIj3bfo-LzyZvz6bvR7PRtN53MRqohVRr1iresr3tNa9zopuVY61bWFbSKMcoU11jOeY_LEhOlmqbuOVQt4RpAlwDAjoqnW9219VHsbIuCNJhSwghmmei2RO_lhVgHs5Lhl_DSiM2GDwshQ07WgmCVwoxANpDgkmueH90yCpTrWkqpstbr3WnDfAW9ApeCtHui-3-cWYqF_y7KinLKeBZ4shVQwWSHnXA-SEEwZo1oa04y8GJ3QvDfBohJrExUYK104IdNYoyWrK3KjD77B709_R21kDlD47TPF1OXomJSMtpWuMmdc1SMb6Hy28PKqNyE2uT9vYCXewGZSfAzLeQQo-jOPv0_e_pln31-g12CtGkZvR02HbcPlldO-hgD6OsqECwuZ-jKDXE5Q2I3Q38LsK3TddDV0LA_J0UUgQ</recordid><startdate>20150807</startdate><enddate>20150807</enddate><creator>Kilvaer, Thomas K</creator><creator>Khanehkenari, Mehrdad Rakaee</creator><creator>Hellevik, Turid</creator><creator>Al-Saad, Samer</creator><creator>Paulsen, Erna-Elise</creator><creator>Bremnes, Roy M</creator><creator>Busund, Lill-Tove</creator><creator>Donnem, Tom</creator><creator>Martinez, Inigo Z</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>3HK</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150807</creationdate><title>Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers</title><author>Kilvaer, Thomas K ; Khanehkenari, Mehrdad Rakaee ; Hellevik, Turid ; Al-Saad, Samer ; Paulsen, Erna-Elise ; Bremnes, Roy M ; Busund, Lill-Tove ; Donnem, Tom ; Martinez, Inigo Z</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c715t-dc983d6df2607f7890ff8a65e8c3323c9f0ab9d04401cc776d9e5819feef4eee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Actin</topic><topic>Actins - metabolism</topic><topic>Aged</topic><topic>Antigens</topic><topic>Biology</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Carcinoma, Non-Small-Cell Lung - metabolism</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical medical disciplines: 750</topic><topic>Clinical medicine</topic><topic>Cohort Studies</topic><topic>Correlation</topic><topic>Correlation analysis</topic><topic>Development and progression</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Fibroblasts</topic><topic>Fibroblasts - metabolism</topic><topic>Fibroblasts - pathology</topic><topic>Health aspects</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Immunotherapy</topic><topic>Klinisk medisinske fag: 750</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Markers</topic><topic>Medical disciplines: 700</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medisinske Fag: 700</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Molecular chains</topic><topic>Muscle proteins</topic><topic>Muscles</topic><topic>Neoplasm Staging</topic><topic>Non-small cell lung cancer</topic><topic>Non-small cell lung carcinoma</topic><topic>Observer Variation</topic><topic>Oncology</topic><topic>Oncology: 762</topic><topic>Onkologi: 762</topic><topic>Pathology</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Physiological aspects</topic><topic>Prognosis</topic><topic>Protein Tyrosine Phosphatase, Non-Receptor Type 13 - metabolism</topic><topic>Proteins</topic><topic>Risk factors</topic><topic>Smooth muscle</topic><topic>Squamous cell carcinoma</topic><topic>Statistics, Nonparametric</topic><topic>Stromal Cells - metabolism</topic><topic>Stromal Cells - pathology</topic><topic>Studies</topic><topic>Survival</topic><topic>Tissue Array Analysis</topic><topic>Tumors</topic><topic>VDP</topic><topic>Wound healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kilvaer, Thomas K</creatorcontrib><creatorcontrib>Khanehkenari, Mehrdad Rakaee</creatorcontrib><creatorcontrib>Hellevik, Turid</creatorcontrib><creatorcontrib>Al-Saad, Samer</creatorcontrib><creatorcontrib>Paulsen, Erna-Elise</creatorcontrib><creatorcontrib>Bremnes, Roy M</creatorcontrib><creatorcontrib>Busund, Lill-Tove</creatorcontrib><creatorcontrib>Donnem, Tom</creatorcontrib><creatorcontrib>Martinez, Inigo Z</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints Resource Center</collection><collection>Science in Context</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>NORA - Norwegian Open Research Archives</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kilvaer, Thomas K</au><au>Khanehkenari, Mehrdad Rakaee</au><au>Hellevik, Turid</au><au>Al-Saad, Samer</au><au>Paulsen, Erna-Elise</au><au>Bremnes, Roy M</au><au>Busund, Lill-Tove</au><au>Donnem, Tom</au><au>Martinez, Inigo Z</au><au>Gullberg, Donald</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-08-07</date><risdate>2015</risdate><volume>10</volume><issue>8</issue><spage>e0134965</spage><epage>e0134965</epage><pages>e0134965-e0134965</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Cancer Associated Fibroblasts (CAFs) are thought to regulate tumor growth and metastasis. Fibroblast Activating Protein 1 (FAP-1) is a marker for fibroblast activation and by many recognized as the main marker of CAFs. Alpha Smooth Muscle Actin (α-SMA) is a general myofibroblast marker, and can be used to identify CAFs. This study investigates the prognostic impact of FAP-1 and α-SMA in non-small cell lung cancer (NSCLC) patients and correlates their expression to 105 proteins investigated in the same cohort.
Tumor specimens from 536 NSCLC patients were obtained and tissue micro-arrays were constructed. Immunohistochemistry was used to evaluate the expression of FAP-1 and α-SMA and explore their impact on survival and association with other tumor molecular markers in NSCLC patients.
High expression of FAP-1, but not α-SMA, in squamous cell carcinoma (SCC, P = 0.043, HR = 0.63 95% CI 0.40-0.99) was significantly associated with increased disease-specific survival. FAP-1 and α-SMA were not significantly correlated to each other. Analyses of FAP-1 and α-SMA associated with other tumor-related proteins revealed histotype-specific correlation patterns.
The presence of FAP-1 expressing CAFs is an indicator of positive outcome for NSCLC-SCC patients. In addition, correlation analyses suggest FAP-1 and α-SMA to label different subsets of fibroblasts and their associations with other tumor-related proteins diverge according to histological subtype.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>26252379</pmid><doi>10.1371/journal.pone.0134965</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-6203 |
ispartof | PloS one, 2015-08, Vol.10 (8), p.e0134965-e0134965 |
issn | 1932-6203 1932-6203 |
language | eng |
recordid | cdi_plos_journals_1702213103 |
source | PubMed (Medline); NORA - Norwegian Open Research Archives; Publicly Available Content (ProQuest) |
subjects | Actin Actins - metabolism Aged Antigens Biology Biomarkers, Tumor - metabolism Cancer Cancer patients Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology Care and treatment Chemotherapy Clinical medical disciplines: 750 Clinical medicine Cohort Studies Correlation Correlation analysis Development and progression Disease-Free Survival Female Fibroblasts Fibroblasts - metabolism Fibroblasts - pathology Health aspects Hospitals Humans Immunohistochemistry Immunotherapy Klinisk medisinske fag: 750 Lung cancer Lung diseases Lung Neoplasms - metabolism Lung Neoplasms - pathology Male Markers Medical disciplines: 700 Medical prognosis Medicine Medisinske Fag: 700 Metastases Middle Aged Molecular chains Muscle proteins Muscles Neoplasm Staging Non-small cell lung cancer Non-small cell lung carcinoma Observer Variation Oncology Oncology: 762 Onkologi: 762 Pathology Patient outcomes Patients Physiological aspects Prognosis Protein Tyrosine Phosphatase, Non-Receptor Type 13 - metabolism Proteins Risk factors Smooth muscle Squamous cell carcinoma Statistics, Nonparametric Stromal Cells - metabolism Stromal Cells - pathology Studies Survival Tissue Array Analysis Tumors VDP Wound healing |
title | Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T15%3A14%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%20Associated%20Fibroblasts%20in%20Stage%20I-IIIA%20NSCLC:%20Prognostic%20Impact%20and%20Their%20Correlations%20with%20Tumor%20Molecular%20Markers&rft.jtitle=PloS%20one&rft.au=Kilvaer,%20Thomas%20K&rft.date=2015-08-07&rft.volume=10&rft.issue=8&rft.spage=e0134965&rft.epage=e0134965&rft.pages=e0134965-e0134965&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0134965&rft_dat=%3Cgale_plos_%3EA432850705%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c715t-dc983d6df2607f7890ff8a65e8c3323c9f0ab9d04401cc776d9e5819feef4eee3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1702213103&rft_id=info:pmid/26252379&rft_galeid=A432850705&rfr_iscdi=true |